Review
Biochemistry & Molecular Biology
Kaiyi Yang, Shenghui Feng, Zhijun Luo
Summary: Prostate cancer is a common and deadly cancer in males. Androgen-deprivation therapy is effective in early stage tumors, but many cases progress to metastatic castration-resistant prostate cancer. Existing clinical treatments for advanced prostate cancer have limitations, but gene therapy and viral therapy show promise in controlling the disease.
Article
Biochemistry & Molecular Biology
Bo-Kyeong Jung, Young Jun Kim, JinWoo Hong, Han-Gyu Chang, A-Rum Yoon, Chae-Ok Yun
Summary: Cancer is a complex and deadly disease with limited treatment options. Targeted therapy using small interfering RNA (siRNA) to silence cancer-enriched proteins is a powerful tool, but its application is limited. Oncolytic adenovirus-mediated therapy offers an alternative approach. This study reports the development of two oncolytic adenovirus systems that effectively and persistently target ErbB3.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Xiaoxi Wang, Liping Zhong, Yongxiang Zhao
Summary: Immunogene therapy and oncolytic viruses play important roles in antitumor treatment by enhancing immune effects through genetic engineering and targeting tumor cells specifically for replication and killing, respectively. Modifying the tumor microenvironment is crucial for maximizing the efficacy of oncolytic viruses in combating malignant tumors.
Article
Biochemistry & Molecular Biology
Ana Alfano, Eduardo G. A. Cafferata, Mariela Gangemi, Alejandro Nicola Candia, Cristian M. Malnero, Ismael Bermudez, Mauricio Vargas Lopez, Gregorio David Rios, Cecilia Rotondaro, Nicasio Cuneo, David T. Curiel, Osvaldo L. Podhajcer, Maria Veronica Lopez
Summary: More than one million women worldwide are diagnosed with gynecological cancer each year. Most cases are diagnosed at a late stage due to a lack of symptoms or limited access to prevention in low-resource countries. The oncolytic adenovirus AR2011 has shown promising results in inhibiting the growth of ovarian, uterine, and cervical cancers in vitro, as well as synergizing with chemotherapy. In animal models, AR2011 has demonstrated efficacy in treating ovarian cancer and inducing an abscopal effect. It is a potential novel medicine for intraperitoneal disseminated ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Shanzhi Li, Zhuoxin Li, Shuang Chen, Yilong Zhu, Yiquan Li, Xunzhe Yin, Xiao Li, Guangze Zhu
Summary: In this study, it was demonstrated that the dual-specific antitumor oncolytic adenovirus ATV can inhibit the growth of cervical cancer cells by inducing apoptosis and autophagy. Gene silencing experiments showed that autophagy and the ATG5, ATG12, and ULK1 related pathways induced by ATV were not entirely dependent on LC3 and Beclin-1. Therefore, ATV may have potential applications in tumor gene therapy.
Article
Oncology
Yusuke Mochizuki, Hiroshi Tazawa, Koji Demiya, Miho Kure, Hiroya Kondo, Tadashi Komatsubara, Kazuhisa Sugiu, Joe Hasei, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara
Summary: Study indicates that telomerase-specific oncolytic virotherapy is a promising strategy to enhance the efficacy of PD-1 blockade in osteosarcoma.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Lorella Tripodi, Maria Vitale, Vincenzo Cerullo, Lucio Pastore
Summary: Oncolytic adenoviruses (Onc.Ads) play an interesting role in immunotherapy due to their tumor selectivity, safety, and transgene-delivery capability. Their exceptional immunogenicity leads to a strong T-cell response, potentially making them more effective than current strategies. Various strategies can enhance Onc.Ads' antitumoral efficacy, including tumor microenvironment modulation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Aleksander Gryciuk, Marta Rogalska, Joanna Baran, Lukasz Kuryk, Monika Staniszewska
Summary: In clinical trials, adenovirus vectors are commonly used for gene delivery therapy. Recent developments in molecular techniques have influenced the development of genetically engineered adenovirus vectors with therapeutic potential. This review provides a broad overview of oncolytic therapy and ongoing clinical trials based on oncolytic adenoviruses. HAdV-based strategies in immune oncology show promise in targeting tumors and can change the landscape of cancer treatment.
Review
Microbiology
Ee Wern Tan, Noraini Abd-Aziz, Chit Laa Poh, Kuan Onn Tan
Summary: This article primarily introduces the characteristics of genetically modified adenoviruses as an alternative gene therapy approach for cancer, as well as related oncology clinical studies. The relationship between adenovirus-mediated cancer therapy and tumor biology, tumor microenvironment, and immune response is also discussed.
Article
Cell Biology
Wenjie Li, Yiquan Li, Yingli Cui, Shanzhi Li, Yilong Zhu, Chao Shang, Gaojie Song, Zirui Liu, Zhiru Xiu, Jianan Cong, Tingyu Li, Xiao Li, Lili Sun, Ningyi Jin
Summary: The study found that the recombinant adenovirus Ad-VT significantly inhibited the growth of MCF-7-CSC cells and induced apoptosis, demonstrating a strong inhibitory effect in mice and providing a new theoretical basis for the future treatment of breast cancer.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Shyambabu Chaurasiya, Yuman Fong, Susanne G. Warner
Summary: Oncolytic viruses are a new class of therapeutics that have shown promise in clinical trials, although their anti-tumor efficacy as monotherapy is modest. Most oncolytic viruses are well tolerated, even in immune-suppressed patients, at the currently defined highest feasible doses. Enhancing the potency of oncolytic viruses is necessary for more viruses to be used effectively in clinical settings, thus they are being studied in combination with other therapies for higher therapeutic benefits.
Article
Oncology
Paulo Roberto Del Valle, Samir Andrade Mendonca, Fernanda Antunes, Aline Hunger, Rodrigo E. Tamura, Daniela Bertolini Zanatta, Bryan E. Strauss
Summary: A modified non-replicating adenoviral vector was developed for gene transfer in colorectal cancer cells, showing enhanced sensitivity to chemotherapy and increased cell death rates. The approach may be effective for the treatment of colorectal cancer, allowing for the use of limited drug doses.
CANCER BIOLOGY & THERAPY
(2021)
Article
Genetics & Heredity
Keqing Lu, Fang Wang, Baoliang Ma, Wenjuan Cao, Qi Guo, Hanzhang Wang, Ronald Rodriguez, Zhiping Wang
Summary: This study aimed to evaluate the teratogenic toxicity of bladder cancer-specific oncolytic adenovirus on mice. It found that the adenovirus did not have any discernable effects on fetal mice and F1 development, suggesting it is relatively safe for tumor gene therapy.
CURRENT GENE THERAPY
(2021)
Article
Oncology
Kenneth N. Barton, Farzan Siddiqui, Robert Pompa, Svend O. Freytag, Gazala Khan, Irina Dobrosotskaya, Munther Ajlouni, Yingshu Zhang, Jingfang Cheng, Benjamin Movsas, David Kwon
Summary: The study evaluated the safety and efficacy of oncolytic adenovirus-mediated suicide and IL-12 gene therapy for metastatic pancreatic cancer patients. The results indicated immune system activation in patients after treatment and a median survival of 18.1 months for patients in the third cohort.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Review
Oncology
Junqing Wang, Linyong Du, Xiangjian Chen
Summary: Gastric cancer is a major contributor to global cancer incidence and mortality, threatening the survival and health of people worldwide. Patients with advanced gastric cancer often do not benefit significantly from traditional treatments due to unobvious early symptoms and factors such as tumor heterogeneity and low immunogenicity. Oncolytic virotherapies, as an emerging cancer immunotherapy, have the potential to effectively treat gastric cancer by selectively lysing cancer cells and inducing a systemic antitumor immune response.
FRONTIERS IN ONCOLOGY
(2022)